{'fraction_non_alphanumeric': 0.03873239436619718, 'fraction_numerical': 0.007042253521126761, 'mean_word_length': 6.168067226890757, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long‐term successful treatment of chronic inflammatory demyelinating polyneuropathy‐like polyneuropathy induced by levodopa‐carbidopa intestinal gel with intravenous immunoglobulin

Polyneuropathy (PNP) can develop in approximately 4.1% of patients treated with levodopa-carbidopa intestinal gel (LCIG)[1]. Almost all of these patients suffer from mild, chronic, progressive, axonal, predominantly sensory PNP, and only a few cases with acute-subacute demyelinating neuropathy resistant to immuno-modulatory treatments have been reported thus far[2-4]. However, a recent review recommended to consider these neuropathies axonal because they did not meet the electrodiagnostic criteria for demyelination[1]. Consequently, this may be the first report of a real LCIG-induced demyelinating PNP. This article is protected by copyright. All rights reserved.